已收盤 02-06 16:00:00 美东时间
+0.510
+2.59%
Capricor Therapeutics stellt neue Pipeline-Strategien und Fortschritte bei Duchenne-Muskeldystrophie-Therapien vor Capricor Therapeutics Inc. hat eine neue Unternehmenspräsentation veröffentlicht. Das Unternehmen informiert darin über den aktuellen Stand des Deramiocel-Programms für Duchenne-Muskeld
02-05 22:44
Capricor Therapeutics Unveils Investor Presentation Highlighting Duchenne Program and Exosome Platform Capricor Therapeutics Inc. (Nasdaq: CAPR) has released a new investor presentation detailing updates on its lead program, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The pre
02-05 22:44
今日重点评级关注:韦德布什:维持Replimune Group"跑赢大市"评级,目标价从18美元升至19美元;巴克莱:维持CytomX Therapeutics"超配"评级,目标价从8美元升至10美元
02-05 11:28
Barclays analyst Adrienne Yih maintains Capri Holdings (NYSE:CPRI) with a Overweight and raises the price target from $31 to $32.
02-04 21:59
华盛资讯2月4日讯,卡普里控股公布2025财年Q4业绩,公司Q4营收10.25亿美元,同比下降4.0%,归母净利润1.16亿美元,扭亏为盈。
02-04 13:47
Capri Holdings shares are trading lower. The company reported Q3 financial resu...
02-04 02:26
华盛资讯2月4日讯,卡普里控股公布2025财年Q4业绩,公司Q4营收10.25亿美元,同比下降4.0%,归母净利润0.57亿美元,同比增长1040.0%。
02-04 00:20
Capri Holdings (NYSE:CPRI) just disclosed its Q3 earnings on Tuesday, February ...
02-03 20:26
Capri Holdings (NYSE:CPRI) released its Q3 earnings on Tuesday, February 3, 202...
02-03 19:48
Capri Holdings (NYSE:CPRI) raises FY2026 GAAP EPS guidance from $1.20-$1.40 to $1.30-$1.40 vs $1.17 analyst estimate. Raises FY2026 sales outlook from $3.375 billion-$3.450 billion to $3.450 billion-$3.475 billion vs
02-03 19:47